DataMeds AI, Inc. - Common Stock (MEDS)

Platform to be integrated into Health Lives Here app as a subscription offering

DataMeds AI, Inc. (NASDAQ:MEDS) today announced that it has implemented cost control measures, primarily through reductions in corporate management positions, to focus the workforce spend on commercializing ChemoFx® as a diagnostic lab test to help oncologists inform their chemotherapy regimen selection, initially for gynecologic cancers only.

Leading Health IT Company has Implemented Cost Control Measures and Refocused Remaining Workforce Towards ChemoFx® Commercialization with Hospital Systems, HMOs, GPOs and Cancer Centers

DataMeds AI, Inc. (NASDAQ:MEDS) today announced that its recently acquired CLIA-certified precision oncology laboratory subsidiary Helomics Corporation has received a Medicaid coverage determination in gynecologic cancers for the ChemoFx® Assay.

Humana adds ChemoFx® to its Medicaid Pharmacogenomics Testing coverage policy

DataMeds AI, Inc. (NASDAQ:MEDS) today announced that it has filed DBAs for ‘DataMEDS SI’ and ‘Corexa Health SI’.

Healthcare IT Company and its Subsidiary Undertake Action Following US Government's Updated Nomenclature

DALLAS, Texas, Oct. 1, 2026 - DarkHorse Technologies Inc. (NASDAQ: DRK) CEO Joel Block is giving investors a closer look at the strategy behind the newly rebranded digital infrastructure company, outlining how DarkHorse intends to leverage its existing energized power portfolio to pursue artificial intelligence, high-performance computing (HPC) and inference-focused data center opportunities .

DataMeds AI, Inc. (NASDAQ:MEDS), a healthcare company leveraging its Health IT and physical infrastructure together with its artificial intelligence platform EinsteinRx™ and smart contracts platform PharmacyChain™, today provided a revenue update on Corexa Pharmacy, a division of its wholly owned subsidiary Corexa Health.

September 2026 revenue up more than 66 percent from July 2026 with expansion of retail customer base and Tollo Health pharmaceutical-adjunct product launches

DataMeds AI, Inc. (NASDAQ:MEDS), a healthcare company leveraging its Health IT and physical infrastructure together with its artificial intelligence platform EinsteinRx™ and smart contracts platform PharmacyChain™, and Tollo Health, LLC (“Tollo”), a healthcare company commercializing proprietary medical foods and dietary supplements and, through TolloBio, developing biopharmaceutical candidates, today announced the launch of the Health Lives Here mobile application, initially focused on supporting users of GLP-1 receptor agonist medications.

Healthcare IT Company and Nutritional Products Maker to Work with NFL Alumni Health to Drive Awareness of GLP-1 Telehealth and Pharmacy Services

DataMeds AI, Inc. (NASDAQ:MEDS) announced that its Interim Co-CEO Gerald Commissiong will present “What Patients Really Want” at this year’s National Telehealth and Virtual Care Summit in Las Vegas on Monday, September 28, 2026 at 9:15am PT.

Interim Co-CEO to Discuss Growing Patient Desire to Own Health Data

DataMEDS AI, Inc. (NASDAQ:MEDS) (the “Company” or “DataMEDS”), a Health IT company vertically integrating health data acquisition and transfer, today announced that it launched its new corporate website www.DataMedsAI.com.

Updated Website Aligns with Pending Marketing Initiatives Following Recent Acquisition of Helomics CLIA-certified Laboratory and Litigation Settlement

TAMPA, FL / ACCESS Newswire / September 18, 2026 / DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMeds AI," "DataMEDS," or the "Company"), a healthcare company leveraging its Health IT and physical infrastructure together with its artificial intelligence platform EinsteinRx™ and smart contracts platform PharmacyChain™,today announced that it has settled litigation related to outstanding debt and receivables related to the May 11, 2023 Wellgistics, LLC Membership Purchase Interest Agreement (the "Settlement Agreement") that were previously carried on the Company's balance sheet as liabilities totaling of approximately $19 million. As part of the Settlement Agreement, the Company retired approximately 364,099 common shares of DataMEDS common stock. The Company paid a total of $450,000 in cash for the Settlement Agreement.

Sept. 15, 2026 - Investors looking across emerging-growth and small-cap stocks are watching Veea Inc. (NASDAQ: VEEA), Sphere 3D Corp. d/b/a DarkHorse Technologies (NASDAQ: ANY), DataMEDS AI, Inc. (NASDAQ: MEDS), MySize, Inc. (NASDAQ: MYSZ) and PDS Biotechnology Corporation (NASDAQ: PDSB) as developments spanning AI healthcare, AI infrastructure, GPU computing, defense technology and cancer immunotherapy create potential catalysts across the group.

Acquisition Provides Operational Capital to Drive Health Lives Here Campaign and Expand Services into Cancer Management

All-stock sale gives Axe Compute equity stake in DataMEDS AI; aligns APU’s operating structure with its scaling GPU-as-a-Service business

Leading Healthcare IT Company and Former NFL Players Will Work Together to Provide Rural Communities Access to Telehealth and Pharmacy-based Services Through Health Lives Here Mobile App

This version includes the correct image.

50% off available online at www.TolloHealth.Shop and www.CorexaRx.com